Bone Therapeutics Completes Enrollment for ALLOB Spinal Fusion Study

Bone Therapeutics completed enrollment of 32 patients in the U.S. Phase IIA study of ALLOB® allogeneic bone-cell therapy in lumbar spinal fusion. Following 1-year follow-up, patient data is expected in mid-2019.

The trial is investigating the addition of ALLOB to use of an interbody cage with bone void filler, and will evaluate fusion,...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us